Successful sulfonylurea treatment in a patient with permanent neonatal diabetes mellitus with a novel KCNJ11 mutation

Korean Journal of Pediatrics

Volumn 58, Issue 8, 2015, Pages 309-312

  Ahn, Sung Yeon ^a   Kim, Gu Hwan ^b   Yoo, Han Wook ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

KCNJ11; Permanent neonatal diabetes mellitus; Sulfonylurea compounds

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; C PEPTIDE; GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; ISOPHANE INSULIN;

ARTICLE; BLOOD GLUCOSE MONITORING; CASE REPORT; DIABETIC KETOACIDOSIS; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HYPOGLYCEMIA; INFANT; INTRAUTERINE GROWTH RETARDATION; NEWBORN DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST;

EID: 84939222720     PISSN: 17381061     EISSN: 20927258     Source Type: Journal    
DOI: 10.3345/kjp.2015.58.8.309     Document Type: Article

References (15)

1. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, et al. Activating mutations in the gene encoding the ATPsensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004;350:1838-49.
2. Vaxillaire M, Populaire C, Busiah K, Cave H, Gloyn AL, Hattersley AT, et al. Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. Diabetes 2004;53:2719-22.
3. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006; 355:467-77.
4. Koster JC, Remedi MS, Dao C, Nichols CG. ATP and sulfonylurea sensitivity of mutant ATP-sensitive K+ channels in neonatal diabetes: implications for pharmacogenomic therapy. Diabetes 2005;54:2645-54.
5. Zung A, Glaser B, Nimri R, Zadik Z. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6. 2. J Clin Endocrinol Metab 2004;89:5504-7.
6. Russo L, Iafusco D, Brescianini S, Nocerino V, Bizzarri C, Toni S, et al. Permanent diabetes during the first year of life: multiple gene screening in 54 patients. Diabetologia 2011;54:1693-701.
7. Greeley SA, Naylor RN, Philipson LH, Bell GI. Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment. Curr Diab Rep 2011;11:519-32.
8. Suzuki S, Makita Y, Mukai T, Matsuo K, Ueda O, Fujieda K. Molecular basis of neonatal diabetes in Japanese patients. J Clin Endocrinol Metab 2007;92:3979-85.
9. Gach A, Wyka K, Malecki MT, Noczynska A, Skupien J, Nazim J, et al. Islet-specific antibody seroconversion in patients with long duration of permanent neonatal diabetes caused by mutations in the KCNJ11 gene. Diabetes Care 2007;30:2080-2.
10. Heo JW, Kim SW, Cho EH. Unsuccessful switch from insulin to sulfonylurea therapy in permanent neonatal diabetes mellitus due to an R201H mutation in the KCNJ11 gene: a case report. Diabetes Res Clin Pract 2013;100:e1-2.
11. Kumaraguru J, Flanagan SE, Greeley SA, Nuboer R, Stoy J, Philipson LH, et al. Tooth discoloration in patients with neonatal diabetes after transfer onto glibenclamide: a previously unreported side effect. Diabetes Care 2009;32:1428-30.
12. Tonini G, Bizzarri C, Bonfanti R, Vanelli M, Cerutti F, Faleschini E, et al. Sulfonylurea treatment outweighs insulin therapy in shortterm metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene. Diabetologia 2006;49:2210-3.
13. Iafusco D, Bizzarri C, Cadario F, Pesavento R, Tonini G, Tumini S, et al. No beta cell desensitisation after a median of 68 months on glibenclamide therapy in patients with KCNJ11-associated permanent neonatal diabetes. Diabetologia 2011;54:2736-8.
14. Remedi MS, Agapova SE, Vyas AK, Hruz PW, Nichols CG. Acute sulfonylurea therapy at disease onset can cause permanent remission of KATP-induced diabetes. Diabetes 2011;60:2515-22.
15. Carmody D, Bell CD, Hwang JL, Dickens JT, Sima DI, Felipe DL, et al. Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons. J Clin Endocrinol Metab 2014;99:E2709-14